Economic Atlas
Companies/Zymeworks Inc.
Company profile

Zymeworks Inc.

NASDAQ: ZYME · Healthcare · Biotechnology
Canadian filerHQ Middletown, BCCIK 0001937653Reports USD
#344 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
55C
Revenue TTM
$81.3M
Rev growth YoY (TTM)
-13.0%
Net income (FY)
-$81.1M
Employees
264
as of 2026-08-09
Market cap
$1.7B
as of 2026-08-09

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$106.0M$106.0M2025
Net income-$81.1M-$81.1M2025
Operating income-$92.5M-$92.5M2025
Total assets$346.5M$346.5M2025
Liabilities$78.0M$78.0M2025
Equity$268.5M$268.5M2025

Revenue trend

FY2022 – FY2025 · USD
FY22
FY22
FY22
FY23
FY24
FY25

Revenue by segment

Filed disclosures · FY2025
By product
Milestone Revenue62%
Option Exercise Fee18%
Research Support Payments And Other Service14%
Royalty6%
By geography

Not disclosed.

The read

What is Zymeworks Inc.’s revenue?

Zymeworks Inc. booked $106.0M in FY2025 revenue, growing 39% year over year — faster than most Healthcare companies we track, at a -76.6% net margin.

Peers · Healthcare
Auxly Cannabis Group Inc.76B+Theravance Biopharma Inc75B+Zevra Therapeutics, Inc.70BOwlet, Inc.49DPlanet 13 Holdings Inc.44DSanara MedTech Inc.61C
Key facts
CEOKenneth H. Galbraith
SectorHealthcare
IndustryBiotechnology
HeadquartersMiddletown, BC
ExchangeNASDAQ: ZYME
Employees264
IPO date2017-04-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.